小児患者における尋常性乾癬の治療のためのタピナロフ
小児被験者における尋常性乾癬の治療のためのタピナロフの第3相試験
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
調査の概要
詳細な説明
This study is an open-label study, consisting of a 12-week primary treatment phase and an optional 40-week long-term extension phase in which all eligible subjects will receive tapinarof cream, 1% once daily. At the end of the 12-week primary treatment phase subjects will have the option to continue for 40 additional weeks of treatment. Subjects who choose not to participate in the optional 40-week long-term extension phase will complete a follow-up visit approximately one week after the end of the primary treatment phase.
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Arkansas
-
Rogers、Arkansas、アメリカ、72758
- Northwest Arkansas Clinical Trials Center, PLLC
-
-
California
-
Fountain Valley、California、アメリカ、92708
- First OC Dermatology
-
Rancho Santa Margarita、California、アメリカ、92688
- Mission Dermatology Center
-
-
Florida
-
Miami Lakes、Florida、アメリカ、33014
- San Marcus Research Clinic, Inc.
-
Miami Lakes、Florida、アメリカ、33014
- RM Medical Research
-
Tampa、Florida、アメリカ、33615
- Olympian Clinical Research
-
-
Illinois
-
Chicago、Illinois、アメリカ、60611
- Northwestern University Feinberg School of Medicine
-
-
Indiana
-
Indianapolis、Indiana、アメリカ、46250
- Dawes Fretzin Clinical Research Group
-
West Lafayette、Indiana、アメリカ、47906
- Options Research Group
-
-
Ohio
-
Fairborn、Ohio、アメリカ、45324
- Wright State Physicians Pharmacology Translational Unit
-
-
Oregon
-
Portland、Oregon、アメリカ、97210
- Oregon Dermatology & Research Center
-
-
Washington
-
Spokane、Washington、アメリカ、99202
- Dermatology Specialists of Spokane
-
-
-
-
Alberta
-
Calgary、Alberta、カナダ、T2J7E1
- Dermatology Research Institute Inc.
-
Edmonton、Alberta、カナダ、T5J3S9
- Rejuvenation Laser Dermatology Clinics
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、カナダ、A1E1V4
- Skincare Studio INC
-
-
Ontario
-
Markham、Ontario、カナダ、L3P1X3
- Lynderm Research Inc.
-
Waterloo、Ontario、カナダ、N2J 1C4
- Alliance Clinical Trials
-
Whitby、Ontario、カナダ、L1P0P9
- Whitby Health Centre Dermatology Trials
-
-
Quebec
-
Montreal、Quebec、カナダ、H2X 2V1
- Innovaderm Research, Inc.
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Male and female subjects ages 2 to 17 years with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 3 months prior to the baseline visit
- Subject with plaque psoriasis covering ≥ 3% of the BSA at screening and baseline
- A PGA score of ≥ 2 at screening and baseline
- Female subjects of childbearing potential who are engaging in sexual activity that could lead to pregnancy should use acceptable birth control methods
- Must not be pregnant
- Subject, subject's parent, or legal representative must be capable of giving written informed consent/assent
Exclusion Criteria:
- Psoriasis other than plaque variant
- Any sign of infection of any of the psoriatic lesions
- Immunocompromised at screening
- Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.0x the upper limit of normal (ULN)
- Screening total bilirubin > 1.5x ULN
- Current or chronic history of liver disease
- Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
- Major surgery within 8 weeks prior to baseline or has a major surgery planned during the study
- Known history of clinically significant drug or alcohol abuse in the last year prior to baseline
- Use of any prohibited medication or procedure within the indicated period before the baseline visit until the completion of the study completion or study discontinuation
- History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion may interfere with the subject's participation in the study, interpretation of results, safety of the subject or ability to understand and give informed consent
- Pregnant or lactating females.
- History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation
- Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:オープンラベル
|
applied topically once daily |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
臨床的に重大な臨床検査異常のある被験者の数
時間枠:53週までのスクリーニング
|
53週までのスクリーニング
|
|
|
臨床的に重大なバイタルサイン異常のある被験者の数
時間枠:53週までのスクリーニング
|
53週までのスクリーニング
|
|
|
Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:Screening up to Week 53
|
Incidence, frequency, and duration of treatment emergent AEs and SAEs |
Screening up to Week 53
|
|
Investigator-Assessed Local Tolerability Scale (LTS) Scores
時間枠:Baseline up to Week 52
|
Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale (0-4). Higher LTS scores represent more severe irritation. |
Baseline up to Week 52
|
|
Subject (or Caregiver)-Assessed Local Tolerability Scale (LTS)
時間枠:Baseline up to Week 52
|
Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale (0-4). Higher LTS scores represent more severe irritation. |
Baseline up to Week 52
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Detectable Time-Point (AUC0-t) of tapinarof cream, 1%.
時間枠:Week 4 and Week 12
|
Area under the plasma concentration-time curve from time zero to the last quantifiable time point. |
Week 4 and Week 12
|
|
Maximum Plasma Concentration (Cmax) of tapinarof cream, 1%.
時間枠:Week 4 and Week 12
|
Maximum observed plasma concentration (Cmax). |
Week 4 and Week 12
|
|
Time to Maximum Plasma Concentration (tmax) of tapinarof cream, 1%.
時間枠:Week 4 and Week 12
|
Time to maximum observed plasma concentration obtained directly from the observed concentration. |
Week 4 and Week 12
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Clinical Lead Late-Stage Clinical Development、Organon and Co
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。